Stability and Beyond-Use Date of a Compounded Thioguanine Suspension
- 13 October 2020
- journal article
- research article
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 37 (1) , 23-29
Abstract
Background: Thioguanine (TG) is available only in the form of 40 mg tablets in the United States, and the patient population in which TG is used comprises mostly children. Recognizing its importance as a therapeutic agent and limited stability data for its compounded preparation, the United States Pharmacopoeia has listed TG in its priority list of compounded preparations monographs. Objective: The goal of the present study was to generate stability data and establish a beyond-use date for compounded TG suspension. Methods: Suspensions were compounded using TG tablets and ORA-Plus and ORA-Sweet as vehicles. A robust high-performance liquid chromatography method was developed and validated. TG and guanine (G) in suspensions were quantified immediately after compounding and at regular intervals for 90 days. Physical stability of suspensions was evaluated by observation of organoleptic properties. Results: Results from the study indicate that average TG levels in suspensions remained above 90% of the starting concentration and G formation was less than 2.5% for 90 days. There was no statistically significant difference in the amount of TG degraded over 90 days between suspensions stored at room temperature and in refrigerated conditions. There was also no statistically significant difference in G concentration of suspensions between day 0 and day 90. Conclusion: TG suspensions are stable for 90 days when stored at room temperature or refrigerated conditions and the beyond-use date can be set to 90 days.Keywords
This publication has 12 references indexed in Scilit:
- Tioguanine in the treatment of refractory coeliac disease – a single centre experienceAlimentary Pharmacology & Therapeutics, 2012
- Stability of compounded thioguanine oral suspensionsAmerican Journal of Health-System Pharmacy, 2011
- Application of the iodine–azide postcolumn reaction in RP‐HPLC for the determination of thioguanine in urineJournal of Separation Science, 2008
- 6-Thioguanine Treatment in Inflammatory Bowel Disease: A Critical Appraisal by a European 6-TG Working PartyDigestion, 2006
- The thiopurines: An updateInvestigational New Drugs, 2005
- Improved HPLC methodology for monitoring thiopurine metabolites in patients on thiopurine therapyClinical Biochemistry, 2004
- An improved HPLC method for the quantitation of 6-mercaptopurine and its metabolites in red blood cellsBrazilian Journal of Medical and Biological Research, 2004
- High-performance liquid chromatographic assay of metabolites of thioguanine and mercaptopurine in capillary bloodJournal of Chromatography B, 2003
- 6-Thioguanine in the Treatment of Psoriasis: A Case Report and Literature ReviewJournal of Cutaneous Medicine and Surgery, 2002
- Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanineCancer Treatment Reviews, 2001